Actively Recruiting
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-09-12
236
Participants Needed
5
Research Sites
140 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
CONDITIONS
Official Title
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of high relapse risk myelodysplastic syndrome defined by IPSS-R score of at least 3.5 or IPSS-M risk category intermediate-high, high, or very high
- Eligible for allogeneic hematopoietic stem cell transplantation including matched or mismatched related or unrelated donors
- Karnofsky Performance Status of 60 or greater
- Signed informed consent
You will not qualify if you...
- Severe organ dysfunction including left ventricular ejection fraction less than 50%, oxygen supplementation requirement, serum bilirubin greater than 1.5 times upper limit of normal (unless due to Gilbert syndrome), AST/ALT greater than 5 times upper limit of normal, or estimated glomerular filtration rate less than 50 mL/min
- History of prior allogeneic hematopoietic stem cell transplantation
- Any condition considered unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Peking University People's Hospital
Beijin, Beijing Municipality, China, 100044
Actively Recruiting
2
Zhengzhou University First Affiliated Hospital
Zhengzhou, Henan, China, 450000
Actively Recruiting
3
The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army
Jinan, Shandong, China
Actively Recruiting
4
People's Liberation Army The General Hospital of Western Theater Command
Chengdu, Sichuan, China, 610083
Actively Recruiting
5
The Second Hospital of Hebei Medical University
Shijia Zhuang, China
Actively Recruiting
Research Team
J
Jiang Erlie, doctor
CONTACT
X
Xiao Zhijian, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here